Literature DB >> 8830984

Mechanisms of cytokine induced bone resorption: role of nitric oxide, cyclic guanosine monophosphate, and prostaglandins.

S H Ralston1, P S Grabowski.   

Abstract

We have examined the role of prostaglandins, nitric oxide (NO), and the NO induced effector molecule cyclic-guanosine monophosphate (cGMP) as mediators of cytokine effects on bone resorption in murine calvarial organ cultures. The combination of interleukin-1 beta (IL-1) and tumor necrosis factor alpha (TNF) stimulated NO production, PGE2 production, and bone resorption. The increase in bone resorption was inhibited by the NO synthase inhibitor L-NG-monomethyl arginine (LMMA) and by the cyclo-oxygenase inhibitor indomethacin, indicating that both factors act as mediators of bone resorption induced by IL-1 and TNF. In contrast, interferon gamma (IFN) inhibited bone resorption induced by IL-1, markedly stimulated NO production, but had no effect on IL-1 induced PGE2 production. The suppressive effect of IFN on bone resorption was reversed by LMMA, but enhanced by indomethacin confirming that the inhibitory effect of IFN on cytokine induced resorption is entirely attributable to high levels of NO production. While cytokine induced NO production was accompanied by increased production of cyclic guanosine monophosphate (cGMP), the cGMP agonist 8-bromo-cGMP had no significant effect on bone resorption, suggesting the effects of NO in bone resorption are mediated by other pathways. We conclude that the effect of cytokines on bone resorption are determined by a balance between levels of NO and PGE2; high NO concentrations inhibit bone resorption and antagonize the effects of PGE2, whereas lower concentrations act together with prostaglandins to enhance bone resorption. These observations may be of relevance to the pathogenesis of bone loss in inflammatory diseases such as rheumatoid arthritis (RA) where, IL-1 and TNF production are increased but IFN production is diminished, resulting in modest increases in NO and large increase in PGE production that are pro-resorptive.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8830984     DOI: 10.1016/8756-3282(96)00101-9

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  12 in total

Review 1.  Nitric oxide and bone.

Authors:  R J van't Hof; S H Ralston
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

2.  A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.

Authors:  Hema Kalyanaraman; Ghania Ramdani; Jisha Joshua; Nadine Schall; Gerry R Boss; Esther Cory; Robert L Sah; Darren E Casteel; Renate B Pilz
Journal:  J Bone Miner Res       Date:  2016-09-07       Impact factor: 6.741

3.  Evaluation of the relationship between inducible nitric oxide synthase (iNOS) activity and effects of melatonin in experimental osteoporosis in the rat.

Authors:  G Oktem; S Uslu; S H Vatansever; H Aktug; M E Yurtseven; A Uysal
Journal:  Surg Radiol Anat       Date:  2005-12-15       Impact factor: 1.246

4.  The effect of circulating nitric oxide level on axial bone mineral density in postmenopausal Turkish women with rheumatoid arthritis: A preliminary report.

Authors:  Gunsah Sahin; Hayal Guler; Melek Sezgin; Nurgul Arinci Incel; Gurbuz Polat
Journal:  Rheumatol Int       Date:  2005-12-14       Impact factor: 2.631

5.  iNOS-derived nitric oxide stimulates osteoclast activity and alveolar bone loss in ligature-induced periodontitis in rats.

Authors:  Bruno S Herrera; Rodrigo Martins-Porto; Aline Maia-Dantas; Paula Campi; Luis C Spolidorio; Soraia K P Costa; Thomas E Van Dyke; Robert Gyurko; Marcelo N Muscara
Journal:  J Periodontol       Date:  2011-03-21       Impact factor: 6.993

Review 6.  The Oxygen Paradox, the French Paradox, and age-related diseases.

Authors:  Joanna M S Davies; Josiane Cillard; Bertrand Friguet; Enrique Cadenas; Jean Cadet; Rachael Cayce; Andrew Fishmann; David Liao; Anne-Laure Bulteau; Frédéric Derbré; Amélie Rébillard; Steven Burstein; Etienne Hirsch; Robert A Kloner; Michael Jakowec; Giselle Petzinger; Delphine Sauce; Florian Sennlaub; Isabelle Limon; Fulvio Ursini; Matilde Maiorino; Christina Economides; Christian J Pike; Pinchas Cohen; Anne Negre Salvayre; Matthew R Halliday; Adam J Lundquist; Nicolaus A Jakowec; Fatima Mechta-Grigoriou; Mathias Mericskay; Jean Mariani; Zhenlin Li; David Huang; Ellsworth Grant; Henry J Forman; Caleb E Finch; Patrick Y Sun; Laura C D Pomatto; Onnik Agbulut; David Warburton; Christian Neri; Mustapha Rouis; Pierre Cillard; Jacqueline Capeau; Jean Rosenbaum; Kelvin J A Davies
Journal:  Geroscience       Date:  2017-12-21       Impact factor: 7.713

7.  Idiopathic hypercalciuria: O2(-)NO relationship and altered bone metabolism.

Authors:  L Calò; S Giannini; P Bonvicini; M Nobile; S Cantaro; M Plebani; A Semplicini; A D'Angelo; G Crepaldi
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

8.  Soluble guanylate cyclase as a novel treatment target for osteoporosis.

Authors:  Jisha Joshua; Gerburg K Schwaerzer; Hema Kalyanaraman; Esther Cory; Robert L Sah; Mofei Li; Florin Vaida; Gerry R Boss; Renate B Pilz
Journal:  Endocrinology       Date:  2014-09-04       Impact factor: 4.736

9.  Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity.

Authors:  J Aguirre; L Buttery; M O'Shaughnessy; F Afzal; I Fernandez de Marticorena; M Hukkanen; P Huang; I MacIntyre; J Polak
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

10.  Assessment of the Role of NO-cGMP Pathway in Orthodontic Tooth Movement Using PDE5 Inhibitors: An Animal Study.

Authors:  Amir Hossein Mirhashemi; Mohammad Sadegh Ahmad Akhoundi; Rezvaneh Ghazanfari; Shahroo Etemad-Moghadam; Mojgan Alaeddini; Azam Khorshidian; Ahmad Reza Dehpour; Nafiseh Momeni
Journal:  J Dent (Tehran)       Date:  2016-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.